Trial results

$LBRX — LB-102

LB PHARMACEUTICALS INC (LBRX) LB-102: trial results in schizophrenia, 2027.

Research by Catalyst Intel

The catalyst

"As we advance toward topline results from our Phase 3 NOVA-2 trial in schizophrenia in the first half of 2027, Susan's deep clinical, regulatory, and development expertise will be instrumental in shaping our development strategy and furthering our ability to deliver innovative new medicines to patients with serious neuropsychiatric disorders."

— LB Pharmaceuticals, 8-K filed 2026-09-15 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

LBRX-LB102-2026

Company

LB PHARMACEUTICALS INC

Kind

Trial results

Indication

schizophrenia

Window

2027-01-01 – 2027-06-30

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.